Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
Cantor Fitzgerald maintains Overweight on ORIC stock
Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...
Investing3d
Cantor Fitzgerald maintains Overweight on ORIC stock
On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...
ORIC Pharmaceuticals shares surge on potential data leak
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data. Analyst Prakhar ...
Business Insider3d
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered ... the high-level news commentary “sounds very positive” for mevrometostat and Oric Pharmaceuticals (ORIC). The firm has an Overweight ...
Guggenheim Reiterates “Buy” Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.